JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Viatris Inc

Closed

SectorHealthcare

10.36 0.58

Overview

Share price change

24h

Current

Min

10.3

Max

10.49

Key metrics

By Trading Economics

Income

3B

-4.6M

Sales

328M

3.6B

Dividend yield

4.72

Profit margin

-0.128

Employees

32,000

EBITDA

2.9B

578M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+10.47% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.72%

2.33%

Next Earnings

6 Nov 2025

Next Dividend date

12 Dec 2025

Next Ex Dividend date

21 Nov 2025

Market Stats

By TradingEconomics

Market Cap

1.5B

12B

Previous open

9.78

Previous close

10.36

Technical Score

By Trading Central

Confidence

Bullish Evidence

Viatris Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 Oct 2025, 09:10 UTC

Hot Stocks

Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials -- WSJ

Peer Comparison

Price change

Viatris Inc Forecast

Price Target

By TipRanks

10.47% upside

12 Months Forecast

Average 11.5 USD  10.47%

High 15 USD

Low 8 USD

Based on 4 Wall Street analysts offering 12 month price targets forViatris Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

1

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

8.48 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
help-icon Live chat